Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY3041658 · 5 trials · 4 indications
The HiSCR is defined as at least a 50% reduction in the total abscess and inflammatory nodule count (sum of abscesses and inflammatory nodules \[AN count\]) with no increase in abscess count (A count) and no increase in draining fistulae count (DF count) relative to baseline. Non-responder imputation (NRI): Participants with missing data were considered non-responders.
Number of Participants With incidence and severity of ISR
VAS Score for Injection Site Pain
| Arm | Type | Description |
|---|---|---|
| LY3041658 | EXPERIMENTAL | Participants received 600 mg LY3041658 administered intravenously (IV) once every 2 weeks (Q2W). |
| Placebo | PLACEBO_COMPARATOR | Placebo administered IV. Participants will switch to 600 mg LY3041658 administered IV after week 16. |
| Eltrekibart Cohort 1 | EXPERIMENTAL | Eltrekibart administered subcutaneously (SC) |
| Eltrekibart Cohort 2 | EXPERIMENTAL | Eltrekibart administered SC |
| Eltrekibart Cohort 3 | EXPERIMENTAL | Eltrekibart administered intravenously (IV) |
| Eltrekibart Cohort 4 | EXPERIMENTAL | Eltrekibart administered SC |
| LY3041658 Low Dose | EXPERIMENTAL | LY3041658 administered by subcutaneous (SC) injection. |
| LY3041658 High Dose | EXPERIMENTAL | LY3041658 administered by SC injection. |
| LY3041658 (IV) | EXPERIMENTAL | Single dose of LY3041658, administered as a slow intravenous (IV) infusion in escalating dose cohorts. |
| LY3041658 (SC) | EXPERIMENTAL | Single dose of LY3041658 administered subcutaneously (SC). |
| Name | Type | Description |
|---|---|---|
| Placebo | DRUG | Administered IV |
| LY3041658 | DRUG | Administered IV |
| LY3041658 (SC) | DRUG | Administered SC |
| LY3041658 (IV) | DRUG | Administered as slow IV infusion |
Inclusion Criteria: * Have a diagnosis of HS for at least 6 months * Have HS lesions in at least 2 different anatomic areas * Have inadequate response or intolerance to a 28 day course of oral antibiotics * Have a total count of abscesses and inflammatory nodules greater than or equal to 4 * Agree ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AbbVie, Inc. | ABBV | 5 | PHASE3 | Upadacitinib |
| Incyte Corporation | INCY | 6 | PHASE3 | Povorcitinib |
| Novartis AG Sponsored ADR | NVS | 11 | PHASE3 | Remibrutinib Dose A, Remibrutinib Dose B |
| MoonLake Immunotherapeutics Class A | MLTX | 2 | PHASE3 | Sonelokimab |
| Sanofi SA Sponsored ADR | SNY | 2 | PHASE2 | Brivekimig |
| Pfizer Inc. | PFE | 1 | PHASE2 | Ritlecitinib |
| Merck & Co., Inc. | MRK | 1 | PHASE2 | Tulisokibart |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 1 | PHASE2 | Zasocitinib |
| Zura Bio Limited Class A | ZURA | 1 | PHASE2 | Tibulizumab Dose A, Tibulizumab Dose B |
| Sonoma Pharmaceuticals, Inc. | SNOA | 2 | PHASE1 | SBT777101 |
| Evommune, Inc. | EVMN | 1 | EARLY_PHASE1 | EVO101 |
LY3041658 is an investigational small molecule being studied for hidradenitis suppurativa, a chronic skin disease. It is also being evaluated in healthy participants to assess safety and tolerability. The drug is in clinical development by Eli Lilly and Company and is not yet approved for any use.
LY3041658 is a small molecule being developed by Eli Lilly and Company. Its specific molecular target has not been disclosed in available clinical trial information. The drug is being studied for hidradenitis suppurativa, a skin condition, but its mechanism of action is not publicly detailed.
LY3041658 is being developed by Eli Lilly and Company, a pharmaceutical company traded on the NYSE under the ticker LLY. The drug is an investigational small molecule currently in clinical trials for hidradenitis suppurativa and healthy volunteer studies.
LY3041658 is in Phase 1 clinical development. While one completed trial was listed as Phase 2, the most recent active trial is Phase 1. The drug is investigational and has not received FDA approval. Eli Lilly and Company is conducting trials in healthy participants and those with hidradenitis suppurativa.
LY3041658 has been studied in several clinical trials. NCT02148627 and NCT04653168 were Phase 1 safety studies in healthy participants. NCT04493502 was a Phase 2 study in adults with hidradenitis suppurativa. NCT07545590 is an active Phase 1 study in healthy participants, not yet recruiting.
Yes, LY3041658 is also known as Eltrekibart. A clinical trial titled 'A Study of Eltrekibart (LY3041658) in Healthy Participants' confirms that both names refer to the same investigational drug being developed by Eli Lilly and Company.